Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

• ClinicalTrials.gov Identifier: NCT02471222
• Recruitment Status: Completed
• First Posted: June 15, 2015
• Last Update Posted: August 8, 2017
• Sponsor: Adamas Pharmaceuticals, Inc.
• Information provided by (Responsible Party): Adamas Pharmaceuticals, Inc.

Study Description

Brief Summary:

This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once daily at bedtime for the treatment of walking impairment in MS. ADS-5102 is designed to be administered once daily at bed time, ADS-5102 achieves higher plasma amantadine concentrations in the early morning, sustained throughout the afternoon, and lower concentrations in the evening when patients are sleeping. ADS-5102 is designed to deliver its primary treatment effect during the day, and potentially reduce the adverse events of immediate-release amantadine when the patient is asleep.

Condition or disease	Intervention/treatment	Phase
Walking Impairment; Multiple Sclerosis	Drug: ADS-5102; Other: Placebo	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 60 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
• Study Start Date: May 2015
• Actual Primary Completion Date: June 2016
• Actual Study Completion Date: June 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: ADS-5102 (amantadine HCl extended release)	Drug: ADS-5102; Oral capsules to be administered once daily at bedtime for 4 weeks; Other Name: amantadine HCl extended release
Placebo Comparator: Placebo	Other: Placebo; Oral capsules to be administered once daily at bedtime for 4 weeks

Outcome Measures

Primary Outcome Measures :

1. Safety of ADS-5102 assessed by adverse events, safety-related study drug discontinuations, vital signs, and safety laboratory test [ Time Frame: Up to 4 weeks ]

Secondary Outcome Measures :

1. Timed 25 Foot Walk [ Time Frame: Up to 4 weeks ]
2. Timed Up and go [ Time Frame: Up to 4 weeks ]
3. 2 Minute Walk Test [ Time Frame: Up to 4 weeks ]
4. MS Walking Scale-12 [ Time Frame: Up to 4 weeks ]

Other Outcome Measures:

1. Fatigue Scale for Motor and Cognitive Functions [ Time Frame: Up to 4 weeks ]
2. Beck's Depression Inventory-2 [ Time Frame: Up to 4 weeks ]
3. Brief International Cognitive Assessment for MS [ Time Frame: Up to 4 weeks ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Signed a current IRB-approved informed consent form;
• Male or female subjects between 18 and 70 years of age, inclusive;
• Confirmed diagnosis of Multiple Sclerosis according to the 2010 Revised McDonald criteria;
• On a stable regimen of medications taken specifically to treat MS for at least 30 days prior to screening, and willing to continue the same doses and regimens for the duration of study participation;
• Stable physical activity level for at least 30 days prior to screening and willing to continue without change for the duration of study participation;
• Maximum EDSS score during screening of 6.5;
• Sufficient ambulatory ability to complete two trials of the Timed 25 Foot Walk (T25FW) at the screening visit;
• A score on each completed screening T25FW test between 8 and 45 seconds, inclusive;
• Any other current and allowed prescription/non-prescription medications and/or nutritional supplements taken regularly must have been at a stable dose and regimen for at least 30 days prior to screening, and subject must be willing to continue the same doses and regimens during study participation;
• If taking an antidepressant, must be on a stable dose for at least 60 days prior to screening.

Exclusion Criteria:

• History of seizures within 2 years prior to screening;
• Clinically significant MS relapse with onset less than 30 days prior to screening;
• Presence of vertigo or other vestibular dysfunction that might compromise ability to safely perform the T25FW;
• Received physical therapy within 30 days prior to screening;
• Received systemic steroids within 30 days prior to screening;
• Received dalfampridine, methylphenidate, modafinil, armodafinil, amantadine, and/or any product containing amphetamines, or any treatment specifically for fatigue or to improve walking within 30 days prior to screening;
• Received any botulinum toxin containing product used as antispasmodic agent within 3 months prior to screening;
• History of clinically significant hallucinations due to an MS medication or other/unknown cause, within 2 years prior to screening;
• History of Bipolar Disorder or Psychosis, regardless of treatment;
• Presence of cognitive impairment sufficient, in the opinion of the investigator, to affect the subject's ability to complete study assessments, or which would not be in the subject's best interest to participate in the study;
• History of stroke or TIA within 2 years prior to screening;
• History of cancer within 5 years;
• Presence of untreated angle closure glaucoma;
• If female, is pregnant or lactating;
• If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize a highly effective hormonal method of contraception (an IUD, or vasectomized male partner is also acceptable), in combination with a barrier method, from screening through at least 4 weeks after the completion of study treatment;
• Treatment with an investigational drug or device within 30 days prior to screening;
• Treatment with an investigational biologic within 6 months prior to screening;
• Current participation in another clinical trial;
• Planned elective surgery during study participation.

Contacts and Locations

Locations

United States, Arizona

Phoenix, Arizona, United States, 85018

United States, Colorado

Aurora, Colorado, United States, 80045

United States, Florida

Sarasota, Florida, United States, 34239

United States, Georgia

Atlanta, Georgia, United States, 30309

United States, Illinois

Northbrook, Illinois, United States, 60062

United States, Minnesota

Rochester, Minnesota, United States, 55905

United States, Nebraska

Lincoln, Nebraska, United States, 68506

United States, New Mexico

Albuquerque, New Mexico, United States, 87131

United States, New York

Patchogue, New York, United States, 11772

United States, North Carolina

Raleigh, North Carolina, United States, 27607

United States, Ohio

Cleveland, Ohio, United States, 44195

United States, Oklahoma

Oklahoma City, Oklahoma, United States, 73104

United States, Tennessee

Franklin, Tennessee, United States, 37064

United States, Texas

Dallas, Texas, United States, 75214

United States, Washington

Kirkland, Washington, United States, 11772

Sponsors and Collaborators

Adamas Pharmaceuticals, Inc.

More Information

• Responsible Party: Adamas Pharmaceuticals, Inc.
• ClinicalTrials.gov Identifier: NCT02471222
• Other Study ID Numbers: ADS-AMT-MS201
• First Posted: June 15, 2015
• Last Update Posted: August 8, 2017
• Last Verified: August 2017

Additional relevant MeSH terms:

Multiple Sclerosis; Sclerosis; Amantadine; Pathologic Processes; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Antiparkinson Agents; Anti-Dyskinesia Agents; Antiviral Agents; Anti-Infective Agents; Dopamine Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Physiological Effects of Drugs; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents